124 related articles for article (PubMed ID: 11408935)
1. Clinical significance of plasma nucleosome levels in cancer patients.
Kuroi K; Tanaka C; Toi M
Int J Oncol; 2001 Jul; 19(1):143-8. PubMed ID: 11408935
[TBL] [Abstract][Full Text] [Related]
2. Plasma Nucleosome Levels in Node-Negative Breast Cancer Patients.
Kuroi K; Tanaka C; Toi M
Breast Cancer; 1999 Oct; 6(4):361-364. PubMed ID: 11091744
[TBL] [Abstract][Full Text] [Related]
3. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
Goble S; Bear HD
Surg Clin North Am; 2003 Aug; 83(4):943-71. PubMed ID: 12875604
[TBL] [Abstract][Full Text] [Related]
4. Prediction of response to docetaxel by CYP3A4 mRNA expression in breast cancer tissues.
Miyoshi Y; Ando A; Takamura Y; Taguchi T; Tamaki Y; Noguchi S
Int J Cancer; 2002 Jan; 97(1):129-32. PubMed ID: 11774254
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.
Francis P; Crown J; Di Leo A; Buyse M; Balil A; Andersson M; Nordenskjöld B; Lang I; Jakesz R; Vorobiof D; Gutiérrez J; van Hazel G; Dolci S; Jamin S; Bendahmane B; Gelber RD; Goldhirsch A; Castiglione-Gertsch M; Piccart-Gebhart M;
J Natl Cancer Inst; 2008 Jan; 100(2):121-33. PubMed ID: 18182617
[TBL] [Abstract][Full Text] [Related]
6. Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials.
Sparano JA
Clin Breast Cancer; 2000 Apr; 1(1):32-40; discussion 41-2. PubMed ID: 11899388
[TBL] [Abstract][Full Text] [Related]
7. Docetaxel (Taxotere): an effective agent in the management of second-line breast cancer.
van Oosterom AT
Semin Oncol; 1995 Dec; 22(6 Suppl 13):22-8. PubMed ID: 8604449
[TBL] [Abstract][Full Text] [Related]
8. Docetaxel vs mitomycin plus vinblastine in anthracycline-resistant metastatic breast cancer.
Nabholtz JM; Thuerlimann B; Bezwoda WR; Melnychuk D; Deschênes L; Douma J; Vandenberg TA; Rapoport B; Rosso R; Trillet-Lenoir V; Drbal J; Aapro MS; Alaki M; Murawsky M; Riva A
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):25-30. PubMed ID: 9364538
[TBL] [Abstract][Full Text] [Related]
9. Detection of Survivin-expressing circulating cancer cells in the peripheral blood of breast cancer patients by a RT-PCR ELISA.
Yie SM; Luo B; Ye NY; Xie K; Ye SR
Clin Exp Metastasis; 2006; 23(5-6):279-89. PubMed ID: 17086357
[TBL] [Abstract][Full Text] [Related]
10. Docetaxel vs doxorubicin in metastatic breast cancer resistant to alkylating chemotherapy.
Chan S
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):19-24. PubMed ID: 9364537
[TBL] [Abstract][Full Text] [Related]
11. [A case of docetaxel-resistant breast cancer responsive to paclitaxel therapy].
Oura S; Tanino H; Yoshimasu T; Sakurai T; Nakamura T; Kokawa Y; Matsuyama K; Naito Y
Gan To Kagaku Ryoho; 2001 Apr; 28(4):511-4. PubMed ID: 11329786
[TBL] [Abstract][Full Text] [Related]
12. A rapid and systematic review of the effectiveness and cost-effectiveness of the taxanes used in the treatment of advanced breast and ovarian cancer.
Lister-Sharp D; McDonagh MS; Khan KS; Kleijnen J
Health Technol Assess; 2000; 4(17):1-113. PubMed ID: 11074389
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer.
Valero V; Holmes FA; Walters RS; Theriault RL; Esparza L; Fraschini G; Fonseca GA; Bellet RE; Buzdar AU; Hortobagyi GN
J Clin Oncol; 1995 Dec; 13(12):2886-94. PubMed ID: 8523051
[TBL] [Abstract][Full Text] [Related]
14. Docetaxel: an update of its use in advanced breast cancer.
Figgitt DP; Wiseman LR
Drugs; 2000 Mar; 59(3):621-51. PubMed ID: 10776837
[TBL] [Abstract][Full Text] [Related]
15. [Intra-arterial infusion chemotherapy with docetaxel for locally advanced breast cancer and inflammatory breast cancer].
Doi K; Ohchi T; Kudo S; Takahashi M; Sakamoto T; Ochiai T; Sakae T; Ishihara A
Gan To Kagaku Ryoho; 2000 Oct; 27(12):1823-5. PubMed ID: 11086421
[TBL] [Abstract][Full Text] [Related]
16. A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancer.
Adachi I; Watanabe T; Takashima S; Narabayashi M; Horikoshi N; Aoyama H; Taguchi T
Br J Cancer; 1996 Jan; 73(2):210-6. PubMed ID: 8546908
[TBL] [Abstract][Full Text] [Related]
17. [Docetaxel therapy against anthracycline resistant breast cancer].
Oura S; Sakurai T; Yoshimura G; Tamaki T; Umemura T; Kokawa Y; Naito Y; Suzuma T; Tanino H
Gan To Kagaku Ryoho; 1999 May; 26(6):781-8. PubMed ID: 10410147
[TBL] [Abstract][Full Text] [Related]
18. [Efficacy of docetaxel for recurrent breast cancer: evaluation based on chemosensitivity test and clinical response].
Sakurai T; Tanino H; Oura S; Suzuma T; Yamamiti N; Yoshimasu T; Sakurai T; Naito Y
Gan To Kagaku Ryoho; 2000 Mar; 27(3):423-7. PubMed ID: 10740636
[TBL] [Abstract][Full Text] [Related]
19. Docetaxel, a promising novel chemotherapeutic agent in advanced breast cancer.
Salminen E; Bergman M; Huhtala S; Jekunen A; Ekholm E
Anticancer Res; 2000; 20(5C):3663-8. PubMed ID: 11268436
[TBL] [Abstract][Full Text] [Related]
20. Docetaxel monotherapy in heavily pretreated metastatic breast cancer: a multicenter, community-based feasibility trial.
Schmidinger M; Budinsky AC; Wenzel C; Locker GJ; Pluschnig U; Brodowicz T; Kubista E; Maca S; Zabernigg A; Ilsinger P; Seewann L; Hojas S; Blach M; Zielinski CC; Steger GG
Cancer Chemother Pharmacol; 2001; 47(1):57-62. PubMed ID: 11221963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]